CASP3 and Pelizeaus-Merzbacher spectrum disorder: rHIgM22-mediated reduction of caspase 3 activity [40] on oligodendrocytes represents a novel therapeutic approach for many neurological diseases in which neurons and axons degenerate, such as ALS, PMD, other demyelinating and dysmyelinating diseases, and possibly spinal cord injury.